SYRE
Spyre Therapeutics
November 3, 2026 · after-hours
- Rarity
- 1.66
- Peak move
- −11.74%
- Float cap
- $6.4B
Still running — rarity and peak move can only rise from here.
Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting, extended half-life monoclonal antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated conditions. Its pipeline targets the α4β7, TL1A, IL-23 and IL-17A/F pathways, tested as monotherapies and in combinations in ulcerative colitis and Crohn's disease, with additional programs in rheumatic diseases such as rheumatoid and psoriatic arthritis. It has no approved products or commercial revenue.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.